Prebiotic Effects of California Grapes on Gut Health and Cardiometabolic Health in Overweight Men and Women
University of California, Davis · with California Table Grape Commission · NCT06544954
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 45–70 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 40
- US sites recruiting
- 1
- Study start
- May 7, 2025
- Record last updated
- April 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The goal of this clinical trial is to assess the impact of table grape consumption on gut microbiome, intestinal permeability, systemic inflammation, and vascular function in healthy overweight men and women aged 45-70 years. The main questions it aims to answer are:
- Does daily grape intake alter intestinal microbiome composition and intestinal permeability?
- Are changes in gut microbiota and intestinal permeability correlated with changes in cardiometabolic risk factors (inflammation, vascular function, lipid profiles)?
- Does response to grape intake on gut microbiota, intestinal permeability, cardiometabolic and inflammatory markers differ between men and women?
- Are metabolic pathways modified by grape consumption able to explain the link between gut health and cardiometabolic factors?
Researchers will compare freeze-dried grape powder to placebo powder to see if grape powder improves cardiometabolic risk factors.
Participants will
- Consume the powder dissolved in water twice daily for 3 weeks
- Follow their usual diet, modified to limit polyphenol-rich foods
- Visit the clinic at the beginning and end of the intervention for vascular measurements and blood sample collection
- Complete a 3-day 24-hour dietary recall and collect stool sample before each visit
Being studied: Freeze-dried grape powder; Placebo powder
Conditions: Arterial Stiffness; Blood Pressure; Dysbiosis; Inflammation; Permeability; Increased
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- post-menopausal women (cessation of menstruation for minimum two years)
- overweight and obese (BMI between 25-35 kg/m2)
- stable treatment for type 2 diabetes or metabolic syndrome
- ability to understand the intervention concept and written consent to participate
- willingness to accept randomization, undergo testing and intervention procedures, and deliver stool and blood samples
Exclusion Criteria
- menopausal hormone replacement therapy started within less than 6 months
- antibiotics, prebiotics within last 3 months
- antidiabetic treatment involving insulin (for type 1 diabetes)
- vegetarian/vegan and not able to follow modified diet
- any serious medical condition including but not limited to coronary artery disease, uncontrolled hypertension, stroke, congestive heart failure, insulin-dependent diabetes, liver disease, active cancer and anemia
- psychiatric disease that interferes with the understanding and implementation of the intervention
- history of eating disorders such as bulimia nervosa, anorexia nervosa, severe binge eating disorder in the last 5 years
- history of substance abuse or alcohol abuse
- involvement in a weight loss intervention program (including anti-obesity medication) within last 3 months or have had bariatric surgery
- current smokers (within last 180 days)
- use of dietary supplements containing polyphenols in the past 1 month
- strenuous exercise greater than 10 hours per week
Recruiting US locations
Ragle Human Nutrition Center
Davis, CA 95616
Site contact: Jody Randolph · 530-752-7620 · jmrandolph@ucdavis.edu
Study contacts (from the official record)
- Dragan Milenkovic, PhD · (530) 219-5872 · dmilenkovic@ucdavis.edu
- Shannon H Trinh, MS, RD · (408) 802-9356 · shtrinh@ucdavis.edu
Similar studies in California
All weight loss studies in California →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–55
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
AstraZeneca
- Location
- Glendale, CA + 1 other US site
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
TIXiMED, Inc.
- Location
- Chula Vista, CA
- Eligibility basics
- Ages 18–70
- RecruitingHealthy volunteersPhase 1
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Regeneron Pharmaceuticals
- Location
- Glendale, CA
- Eligibility basics
- Ages 18–65